Thursday, November 12, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 17, 2026

Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally

View original at globenewswire.com
Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally Stellantis, Wayve, and Uber are collaborating to develop and deploy L4 driverless mobility services By combining Stellantis’ world-class vehicle L4-Ready Platforms™, Wayve’s advanced AI Driver…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Successfully scaling autonomous mobility requires seamlessly combining the right vehicles, technology, and platform.

    60% confidence

  • Uber has completed more than 75 billion trips since its founding in 2010.

    60% confidence

  • The three-way partnership signals industry convergence around Wayve's technology as the leading approach to scale autonomous vehicles globally.

    60% confidence

  • The collaboration will deliver smarter, safer, and more efficient mobility by combining Stellantis' L4-Ready Platforms with Wayve's adaptive AI and Uber's global network to accelerate AV deployment that meets real customer needs at scale.

    60% confidence

  • Wayve's AI driving technology is designed to adapt across different regions and driving conditions without relying on city-by-city mapping or re-engineering, enabling faster and more cost-effective expansion.

    60% confidence

Data points we hold from this source

Uber Technologies · trips completed75 billion_trips
Uber Technologies · founding year2010 year
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com
Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally — Source | Via News | Via News